Litcius/Paper detail

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Amy S. Ruppert, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutré, Jennifer R. Brown, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, John C. Byrd, Sumithra J. Mandrekar, Jennifer A. Woyach

2021Leukemia17 citationsDOIOpen Access PDF

Topics & Concepts

IbrutinibBendamustineMedicineInternal medicineAdverse effectRituximabCumulative incidenceGastroenterologyChronic lymphocytic leukemiaLymphomaLeukemiaCohortChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentGastrointestinal Tumor Research and Treatment
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202 | Litcius